1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2023-11-01
|
| Collection: | Journal for ImmunoTherapy of Cancer |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|